收藏切换
Quantitative evaluation of selective Janus kinase inhibitors for atopic dermatitis
收藏切换
PDF
Yue ZHAO1, Hao-tian YANG1, Chao-jun XUE1, Xiao LI1, Xiao-yu JU2, Qian ZHAO2, Zhan-jun DONG1, 3
Chinese Journal of New Drugs and Clinical Remedies | 2024, 43(5) : 374 - 379
Less
收藏切换
Chinese Journal of New Drugs and Clinical Remedies | 2024, 43(5): 374-379
Original Article
Quantitative evaluation of selective Janus kinase inhibitors for atopic dermatitis
Full
Yue ZHAO1, Hao-tian YANG1, Chao-jun XUE1, Xiao LI1, Xiao-yu JU2, Qian ZHAO2, Zhan-jun DONG1, 3
Affiliations
  • 1.Department of Pharmacy, Hebei General Hospital, Shijiazhuang HEBEI 050057, China
  • 2.Department of Pharmacy, Hebei Provincial Hospital of Chinese Medicine, Shijiazhuang HEBEI 050011, China
  • 3.Hebei Key Laboratory of Clinical Pharmacy,Shijiazhuang HEBEI 050051, China
Published: 2024-05-25 doi: 10.14109/j.cnki.xyylc.2024.05.11
Outline
收藏切换
AIM

To quantitative evaluate of selective Janus kinase inhibitors in treatment of atopic dermatitis, and provide scientific basis for drug selection and clinical rational drug use.

METHODS

According to the Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions (the Second Edition), a comprehensive evaluation of upadacitinib and abrocitinib was conducted from five aspects of pharmaceutical characteristics, efficacy, safety, economy,and other attributes, and scores were assigned.

RESULTS

The total scores of upadacitinib and abrocitinib were 80.5 and 80.2 respectively. Upadacitinib and abrocitinib had definite therapeutic effects in terms of itching relief, and skin lesion clearance. But when combined with topical corticosteroids and other drugs, the improvement in efficacy of abrocitinib was better than that of upadacitinib. Upadacitinib had a wider range of applicability compared to abrocitinib, but the incidence of adverse reactions in the blood system of abrocitinib was lower than that of upadacitinib. Upadacitinib and abrocitinib were recommended for admission.

CONCLUSION

Abrocitinib is suitable for patients who seek quick results and build confidence, as well as those who need to flexibly adjust treatment plans based on their condition. Upadacitinib is preferred for adolescents over 12 years old, patients with severe renal insufficiency, or concomitant diseases such as rheumatoid arthritis and ulcerative colitis.

upadacitinib  /  abrocitinib  /  Janus kinase inhibitors  /  dermatitis, atopic  /  drug evaluation
Yue ZHAO, Hao-tian YANG, Chao-jun XUE, Xiao LI, Xiao-yu JU, Qian ZHAO, Zhan-jun DONG. Quantitative evaluation of selective Janus kinase inhibitors for atopic dermatitis[J]. Chinese Journal of New Drugs and Clinical Remedies, 2024 , 43 (5) : 374 -379 . DOI: 10.14109/j.cnki.xyylc.2024.05.11
Year 2024 volume 43 Issue 5
PDF
397
191
Cite this Article
BibTeX
Article Info
doi: 10.14109/j.cnki.xyylc.2024.05.11
  • Receive Date:2023-11-20
  • Online Date:2026-03-20
  • Published:2024-05-25
Article Data
Affiliations
History
  • Received:2023-11-20
  • Accepted:2024-04-23
Funding
Affiliations
    1.Department of Pharmacy, Hebei General Hospital, Shijiazhuang HEBEI 050057, China
    2.Department of Pharmacy, Hebei Provincial Hospital of Chinese Medicine, Shijiazhuang HEBEI 050011, China
    3.Hebei Key Laboratory of Clinical Pharmacy,Shijiazhuang HEBEI 050051, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyylczz/EN/10.14109/j.cnki.xyylc.2024.05.11
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT